Ticagrelor Tablet, Film Coated
Product Images NDC 0480-2695

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 0480-2695). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

New1 (Image 1)

A cumulative percentage line graph comparing two drugs, Ticagrelor 90 mg and Clopidogrel, over 360 days from the first study drug dose. The graph includes patient risk numbers and event data, showing Ticagrelor with a slightly higher cumulative percentage than Clopidogrel.*

FDA Label Image

New9 (Image 10)

A forest plot chart showing the mean effect and 90% confidence interval (CI) of ticagrelor drug interactions with various drugs (Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, Cyclosporine) at specific doses. The x-axis measures change relative to the interacting drug alone, with pharmacokinetic parameters Cmax and AUC represented by squares and triangles respectively. Dose adjustment recommendations are included, indicating maximum simvastatin dose and no dose adjustments for others except monitoring digoxin levels.*

FDA Label Image

New10 (Image 11)

A cumulative incidence Kaplan-Meier curve comparing the percentage of patients with events over 360 days from randomization between Ticagrelor 90 mg and Clopidogrel in a clinical study. The solid line represents Ticagrelor 90 mg, and the dashed line represents Clopidogrel. The chart includes patient numbers at risk over time and a summary table with hazard ratio and p-value.*

FDA Label Image

New11 (Image 12)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals (CI) for various patient characteristics, treatment approaches, and demographic subgroups between Ticagrelor and Clopidogrel efficacy. The horizontal axis shows HR values with Ticagrelor favored on the left and Clopidogrel on the right, accompanied by sample sizes and event rates for each group.*

FDA Label Image

New12 (Image 13)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across different ASA dose categories (>=300 mg, >100 to <300 mg, <=100 mg) in US and non-US regions. The x-axis quantifies comparative effectiveness, with Ticagrelor better on the left and Clopidogrel better on the right, including data on patient numbers and events for each group.*

FDA Label Image

New13 (Image 14)

A cumulative percentage line graph comparing outcomes over days from randomization among three groups: Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo. The x-axis represents days from randomization (up to 1320 days), and the y-axis represents cumulative percent. The graph includes patient counts at risk at various time points and statistical data including number of events, Kaplan-Meier percentages at 36 months, hazard ratios with confidence intervals, and p-values for each Ticagrelor group versus placebo.*

FDA Label Image

New14 (Image 15)

A forest plot graph showing the hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor to placebo across various patient characteristics and subgroups. The horizontal axis ranges from Ticagrelor favoring (left) to placebo favoring (right). The plot includes data points for overall treatment effect, age group, sex, race, weight, BMI, geography, medical history, and other clinical factors, illustrating relative treatment outcomes in these subpopulations.*

FDA Label Image

New15 (Image 16)

A line graph comparing the cumulative percentage of events over months from randomization between Ticagrelor and placebo groups. The x-axis shows months up to 54, and the y-axis shows cumulative percentage up to 14%. Two lines represent Ticagrelor (solid) and placebo (dashed) treatments, with event counts and patient numbers at risk noted below the graph.*

FDA Label Image

New16 (Image 17)

A forest plot chart depicting hazard ratios (HR) with 95% confidence intervals (CI) for various patient subgroups comparing Ticagrelor and placebo effects. The chart shows multiple characteristics such as age, sex, race, body mass index, geographic region, aspirin dose, eGFR, insulin use, history of angina, coronary disease, PCI, CABG, smoking, and diabetes duration. Each subgroup lists HR values, event counts, and indicates whether Ticagrelor or placebo is favored.*

FDA Label Image

New17 (Image 18)

A line graph comparing the cumulative percentage of events over days from randomization between Ticagrelor 90 mg twice daily and placebo groups. The graph includes a legend with event counts, total participants, and Kaplan-Meier percentages, as well as a table showing the number of participants at risk over time for both groups.*

FDA Label Image

New18 (Image 19)

A forest plot graph comparing Ticagrelor versus placebo across various patient characteristics, showing hazard ratios (HR) with 95% confidence intervals. The chart displays subgroups by age, sex, race, weight, BMI, geographic region, diagnosis, diabetes, hypertension, prior conditions, and smoking status, visually indicating the relative efficacy or risk for Ticagrelor compared to placebo.*

FDA Label Image

New2 (Image 2)

A bar graph showing the percentage of patients who experienced an event following coronary artery bypass grafting (CABG) over a series of days. The x-axis represents days (1 through 8 or more), and the y-axis shows the percentage of patients. Bars compare two groups labeled T and C for each day, with numerical data on patients provided below the x-axis.*

FDA Label Image

New (Image 20)

Label for Ticagrelor Tablets 60 mg oral film-coated tablets, supplied in a package of 60 tablets. The label includes dispensing instructions for pharmacists, storage conditions at 25°C with permitted excursions, a warning to keep out of reach of children, and manufacturer details listing Watson Pharma Private Limited in India and Teva Pharmaceuticals in Parsippany, NJ. The label also features the NDC code 0480-2688-06 and a barcode.*

FDA Label Image

New (Image 21)

Label for Ticagrelor Tablets 90 mg film-coated oral tablets, with a quantity of 60 tablets. The label includes storage instructions, a warning to keep out of reach of children, and manufacturer information for Teva Pharmaceuticals, Inc., noting that the product is made by Watson Pharma Private Limited in India. The NDC is 0480-2695-06.*

FDA Label Image

New3 (Image 3)

A line graph comparing the cumulative percentage of events over months from randomization between Ticagrelor and placebo groups. The solid line represents Ticagrelor, and the dashed line represents placebo. The x-axis shows months from 0 to 54, and the y-axis shows cumulative percentage from 0 to 7%. A table below the graph indicates the number of patients at risk over time for both groups.*

FDA Label Image

New4 (Image 4)

A Kaplan-Meier cumulative incidence graph comparing Ticagrelor 90 mg twice daily with placebo over approximately 34 days from randomization. The y-axis shows cumulative percentage, and the x-axis depicts days from randomization. The graph includes a risk table showing patient counts over time for each group.*

FDA Label Image

Chemical Structure (Image 5)

Chemical structure of ticagrelor showing its molecular arrangement, including a fused heterocyclic ring system, hydroxyl groups, and difluorophenyl and ethylthio substituents.*

FDA Label Image

New5 (Image 6)

A line graph comparing platelet aggregation inhibition (IPA) percentage induced by 20uM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. Ticagrelor achieves the highest IPA rapidly, plateauing near 90%. Clopidogrel shows a moderate increase, reaching about 50%. Placebo remains near baseline around 10%. Error bars indicate variability at each time point.*

FDA Label Image

New6 (Image 7)

A line graph comparing the IPA (%) induced by 20uM ADP over time for Ticagrelor, Clopidogrel, and placebo. The x-axis represents time in days (main graph) with an inset showing hours, and the y-axis shows IPA percentage. Ticagrelor and Clopidogrel display higher IPA values over time, while placebo remains low.*

FDA Label Image

New7 (Image 8)

A mean effect and 90% confidence interval chart showing the impact of intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment on Ticagrelor pharmacokinetics. The chart compares Cmax and AUC values relative to reference, with recommendations indicating no dose adjustment is necessary for these factors.*

FDA Label Image

New8 (Image 9)

A chart titled 'Mean effect and 90% CI' showing the interaction effects of various drugs on Ticagrelor and another compound labeled AR-C124910XX. The horizontal axis represents the change relative to reference, with data points for Cmax and AUC. It lists interacting drugs such as Ketoconazole, Diltiazem, Rifampin, Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, Morphine, and Fentanyl, along with recommendations regarding dose adjustments or concomitant use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.